Blog
RSS FeedPosted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 01 Jul 2022
Public Summary Documents – March 2022 PBAC meeting
1 July 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2022 PBAC ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 28 May 2022
Where is the PHARMAC review?
28 May 2022 - “It has been three months to the day since the Minister received the PHARMAC review, why ...
Posted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 14 Apr 2022
Public summary documents – December 2021 PBAC meeting (first time decisions not to recommend, deferrals and other matters)
14 April 2022 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the December ...
Posted by Michael Wonder on 13 Apr 2022
ICER releases draft evidence report on gene therapy for beta thalassaemia
13 April 2022 - Public comment period now open until 10 May 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 09 Apr 2022
Life Saving Drugs Program – medicines reviews recommendations
7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...
Posted by Michael Wonder on 01 Apr 2022
Public Summary Documents – December 2021 PBAC meeting
1 April 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the December 2021 PBAC ...
Posted by Michael Wonder on 01 Apr 2022
ACE releases latest trance of drug guidances (April 2022)
1 April 2022 - The Agency for Clinical Effectiveness has released another batch of drug guidances. ...
Posted by Michael Wonder on 28 Mar 2022
ICER publishes evidence report on treatments for COVID-19
28 March 2022 - Current evidence suggests all four drugs under review have prices reasonably aligned with patient benefits. ...
Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...